194 related articles for article (PubMed ID: 32227579)
21. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract][Full Text] [Related]
22. Tumor-Infiltrating CD8+ T Cells Driven by the Immune Checkpoint-Associated Gene IDO1 Are Associated With Cervical Cancer Prognosis.
Zhang S; Wan J; Chen M; Cai D; Xu J; Chen Q
Front Oncol; 2021; 11():720447. PubMed ID: 34778035
[TBL] [Abstract][Full Text] [Related]
23. GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer.
Wei JL; Wu SY; Yang YS; Xiao Y; Jin X; Xu XE; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281987
[TBL] [Abstract][Full Text] [Related]
24. Understanding the role of the kynurenine pathway in human breast cancer immunobiology.
Heng B; Lim CK; Lovejoy DB; Bessede A; Gluch L; Guillemin GJ
Oncotarget; 2016 Feb; 7(6):6506-20. PubMed ID: 26646699
[TBL] [Abstract][Full Text] [Related]
25. Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Jul; 8(29):47400-47411. PubMed ID: 28537889
[TBL] [Abstract][Full Text] [Related]
26. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
27. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
28. p38β - MAPK11 and its role in female cancers.
Katopodis P; Kerslake R; Zikopoulos A; Beri N; Anikin V
J Ovarian Res; 2021 Jun; 14(1):84. PubMed ID: 34174910
[TBL] [Abstract][Full Text] [Related]
29. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
Tan J; Egelston CA; Guo W; Stark JM; Lee PP
EBioMedicine; 2024 Mar; 101():105035. PubMed ID: 38401418
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of indoleamine 2,3-dioxygenase 1
Economopoulou P; Kladi-Skandali A; Strati A; Koytsodontis G; Kirodimos E; Giotakis E; Maragoudakis P; Gagari E; Maratou E; Dimitriadis G; Kotsantis I; Vagia E; Anastasiou M; Gkotzamanidou M; Kavourakis G; Lianidou E; Psyrri A
ESMO Open; 2020 May; 5(3):e000646. PubMed ID: 32414944
[TBL] [Abstract][Full Text] [Related]
31. Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy.
Georganaki M; Ramachandran M; Tuit S; Núñez NG; Karampatzakis A; Fotaki G; van Hooren L; Huang H; Lugano R; Ulas T; Kaunisto A; Holland EC; Ellmark P; Mangsbo SM; Schultze J; Essand M; Tugues S; Dimberg A
Oncoimmunology; 2020; 9(1):1730538. PubMed ID: 32231867
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory effects of flavonoids isolated from
Kwon M; Ko SK; Jang M; Kim GH; Ryoo IJ; Son S; Ryu HW; Oh SR; Lee WK; Kim BY; Jang JH; Ahn JS
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1481-1488. PubMed ID: 31423846
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
34. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
35. IDO1 Deficiency Does Not Affect Disease in Mouse Models of Systemic Juvenile Idiopathic Arthritis and Secondary Hemophagocytic Lymphohistiocytosis.
Put K; Brisse E; Avau A; Imbrechts M; Mitera T; Janssens R; Proost P; Fallarino F; Wouters CH; Matthys P
PLoS One; 2016; 11(2):e0150075. PubMed ID: 26914138
[TBL] [Abstract][Full Text] [Related]
36. Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity.
El-Zaatari M; Bass AJ; Bowlby R; Zhang M; Syu LJ; Yang Y; Grasberger H; Shreiner A; Tan B; Bishu S; Leung WK; Todisco A; Kamada N; Cascalho M; Dlugosz AA; Kao JY
Gastroenterology; 2018 Jan; 154(1):140-153.e17. PubMed ID: 28912017
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
[TBL] [Abstract][Full Text] [Related]
38. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Yu H; Chen Z; Ballman KV; Watson MA; Govindan R; Lanc I; Beer DG; Bueno R; Chirieac LR; Chui MH; Chen G; Franklin WA; Gandara DR; Genova C; Brovsky KA; Joshi MM; Merrick DT; Richards WG; Rivard CJ; Harpole DH; Tsao MS; van Bokhoven A; Shepherd FA; Hirsch FR
J Thorac Oncol; 2019 Jan; 14(1):25-36. PubMed ID: 30253973
[TBL] [Abstract][Full Text] [Related]
39. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
40. IDO1 is an Integral Mediator of Inflammatory Neovascularization.
Mondal A; Smith C; DuHadaway JB; Sutanto-Ward E; Prendergast GC; Bravo-Nuevo A; Muller AJ
EBioMedicine; 2016 Dec; 14():74-82. PubMed ID: 27889479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
